Notícias

Johnson & Johnson (NYSE:JNJ) already has RYBREVANT approved across multiple EGFR-mutated advanced lung cancer settings. New long-term data are now strengthening the clinical evidence behind the drug. READ ALSO: Pfizer vs. Abbott: Which Dividend Healthcare Stock Offers the Better Risk-Reward? In the final overall-survival analysis of the Phase 3 PAPILLON study, first-line RYBREVANT plus chemotherapy […]

Contineum Therapeutics, Inc. (NASDAQ:CTNM) has received the result biotech investors never want to see: one of its partnered drugs missed the primary endpoint of a Phase 2 trial. JNJ-5120/PIPE-307, which Contineum developed and Johnson & Johnson (NYSE:JNJ) is advancing under a global license and development agreement, failed to demonstrate the required efficacy in the Phase […]

It was reported on September 11 that Apollo Global Management, Inc. (NYSE:APO) is in discussions to acquire Johnson & Johnson (NYSE:JNJ)’s orthopedics business, DePuy Synthes, in a potential transaction valuing the unit at close to $20 billion, according to Bloomberg. The unit, which J&J previously announced plans to separate within an 18-to-24-month timeframe, generated $9.3 […]

Rapid symptom improvement broadens the drug's potential reach, but filing, approval and adoption remain ahead.

Eli Lilly (LLY) grew revenue 49.6% over the last twelve months, the fastest of the six companies in its peer group. It also runs the group's widest operating margin, at 49.7%. Yet its 53.4% stock return ranks only third, behind Merck and Johnson & Johnson, which both grew far more slowly. The open question is how long Mounjaro and Zepbound can carry a lead the stock has not matched.

Intuitive Surgical (ISRG) shares fell 10.4% in the past year, while the S&P 500 returned 16.5%. Much of the market has focused on moderating U.S. procedure growth. The more telling number is 144 trade-ins in fiscal Q2 2026, up from 83 a year earlier. Most came from customers moving to the new da Vinci 5 robot. Those trade-ins matter most if upgrades continue and each surgery also earns more. Is that number a blip, or are customers still trading up.

A bond coupon that felt safe a decade ago may be quietly bleeding your retirement dry, and Dave Ramsey's hurdle-rate math explains exactly why. The question is which assets can actually climb that bar year after year.

When a retiree compares a federally insured CD to a dividend stock that has raised its payout for 70 straight years, the choice turns on a factor most income calculators ignore entirely.

AbbVie and Pfizer are reshaping their growth strategies as new drugs, acquisitions, pipelines and patent challenges shape their outlooks.

As more psychedelic drugs move toward market, developers are testing how far patent protection can extend around familiar compounds.

Bristol Myers Squibb trades at a steep valuation discount, while Johnson & Johnson's stronger margins and lower debt offer stability. But patent cliffs and litigation risks complicate both cases.

AbbVie's management has changed what it puts first on its earnings calls. One growth figure used to open the script. Management last mentioned that figure in the fiscal fourth quarter 2025 call. AbbVie (ABBV) never said it would stop reporting it. So which figure was it, and why did it matter.

Pfizer's COVID products keep shrinking. The company's total revenue has been flat for a year. That makes the best case for this stock easy to miss. It does not rest on the medicines you already know Pfizer (PFE) for. It is not another round of cost cuts either. It rests on a smaller and faster part of the company. So where is that growth coming from.

Patent cliffs have buried lesser pharma dividends, yet these four Big Pharma giants keep raising payouts despite losing blockbuster exclusivities worth billions. Find out which one has held its streak for 64 straight years and whether the 6% yielder is a trap or a genuine opportunity.

Key TakeawaysJohnson & Johnson’s MedTech segment, the business OTTAVA sits inside, grew from $7. 89 billion to $8.

You can take these companies' dividends straight to the bank.

Backed by a former J&J CEO, the startup plans to advance its drug candidates into late-stage trials.

J&J's Caplyta shows rapid and significant improvement in bipolar mania symptoms in a pivotal phase III study.

Alkermes’ results heightened anticipation for a coming readout in 2027. Elsewhere, AbbVie leaned into AI drug discovery and the FDA expanded use of Eli Lilly’s breast cancer pill.

Johnson & Johnson recently reported positive topline Phase 3 results for CAPLYTA (lumateperone) in adults with bipolar I disorder experiencing manic episodes, showing rapid and statistically significant symptom reduction versus placebo, while also highlighting progress across its broader neuropsychiatry portfolio. The data suggest CAPLYTA could potentially treat both depressive and acute manic episodes in bipolar I disorder, meaningfully broadening its clinical role if future regulatory...

Merck (MRK) stock gained about 89% in the year from mid-September 2025, against a 17.1% price gain for the S&P 500. It also beat Johnson & Johnson (JNJ), up 58%, and Eli Lilly (LLY), up 54%. The signs were public long before the run, in what management kept saying about its drug pipeline. The reported sales told a different story.

Johnson & Johnson (JNJ) stock has returned 58% over the past twelve months, second best in a group of six health care companies. Its revenue growth ranks only fourth of the six. Three peers grew faster and returned less, Eli Lilly among them. The price is a bet that the rest of the business keeps growing once shrinking STELARA sales stop dragging on the total.

Boston Scientific (BSX) stock has fallen 55.5% over the past twelve months, and at $43.72 it trades barely above its 52-week low of $42.63. The options market now prices a likely one-year range from $28.46 to $67.16 a share. That band is wide, but it is close to how much the stock has already been moving.

Johnson & Johnson (NYSE: JNJ) received FDA approval for ICOTYDE (icotrokinra) to treat moderate to severe plaque psoriasis in the U.S. ICOTYDE targets the IL-23 receptor and is in Phase III clinical trials for a potential psoriatic arthritis indication. The new therapy extends Johnson & Johnson's immunology pipeline beyond oncology and MedTech into chronic inflammatory skin and joint conditions. The ICOTYDE psoriasis approval and psoriatic arthritis Phase III program deserves weighing...

J&J acquired Intra-Cellular in 2025 for $14.6bn, making it the largest pharma M&A deal in 2025.

Healthcare giant Johnson & Johnson is looking to become a more profitable and faster-growing business.

A three-week study produced rapid symptom improvement, but regulatory approval and commercial conversion remain ahead.

Novo Nordisk's (NVO) US-listed shares declined as the Danish drugmaker unveiled its long-term growth

Intuitive Surgical (ISRG) stock could climb 23.9% to the April high it last fell back from, and you would risk about 5% to find out. That looks like a surgical-robot leader on sale, but the price history disagrees. Over the last two years, none of its visits to this price range turned into a 20% gain before a 5% drop.

Dividend growth stocks have outperformed other types and have done so with significantly less risk.